Kainos Medicine Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
25
- Investments
-
2
- Share Price
-
$16.44
- (As of Thursday Closing)
Kainos Medicine General Information
Description
Developer of novel drugs intended to provide research and develop various medicines for cancers and brain and infectious diseases in South Korea and internationally. The company's product pipeline includes KM-819, which is under phase I clinical study for the treatment of Parkinson's disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is under phase II clinical study to treat HIV/AIDS, thereby providing healthcare companies and healthcare professionals with the various treatment for novel diseases such as brain diseases and cancers.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 3F, Building. A, Korea Bio-Park, 700 Daewangpangyo-ro
- Bundang-gu, Gyeonggi-do
- Seongnam-si, 13488
- South Korea
+82 00-000-0000
Kainos Medicine Timeline
Kainos Medicine Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $16.44 | $16.29 | $9.10 - $19.02 | $231M | 14.1M | 36K | -$0.49 |
Kainos Medicine Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2019 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 |
|---|---|---|---|---|
| EV | 189,988 | 189,988 | 161,753 | 80,738 |
| Revenue | 1,921 | |||
| EBITDA | (6,494) | (6,494) | (7,061) | (2,091) |
| Net Income | (6,805) | (6,805) | (7,228) | (2,314) |
| Total Assets | 4,747 | 4,747 | 7,323 | 7,100 |
| Total Debt | 179 | 179 | 0 | 66 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Kainos Medicine Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kainos Medicine Patents
Kainos Medicine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022247243-A1 | Fas-associated factor 1 (faf1)-loaded exosomes and use thereof as anti-cancer agent | Pending | 30-Mar-2021 | 00000000000 | |
| CA-3215574-A1 | Fas-associated factor 1 (faf1)-loaded exosomes and use thereof as anti-cancer agent | Pending | 30-Mar-2021 | 00000000000 | |
| JP-2022550881-A | N-(1h-imidazol-2-yl)benzamide compounds and pharmaceutical compositions containing said compounds as active ingredients | Pending | 02-Oct-2019 | 0000000000 | |
| US-20220348560-A1 | N-(1h-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | Pending | 02-Oct-2019 | 0000000000 | |
| AU-2020360000-A1 | N-(1h-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | Active | 02-Oct-2019 | C07D403/12 |
Kainos Medicine Executive Team (9)
Kainos Medicine Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| Jaemoon Lee Ph.D | Kainos Medicine | Chief Business Officer, Board Member & Vice President of Biology | 000 0000 |
| Suh Hwan | Kainos Medicine | Board Member | 000 0000 |
Kainos Medicine Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Kainos Medicine Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Kainos Medicine Investments & Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| FAScinate Therapeutics | 01-Aug-2020 | 00000 0000 | 0000 | Drug Discovery | |
| Hana Financial Eleventh Special Purpose Acquisition | 08-Jun-2020 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) | 00000 000 |